|Systematic (IUPAC) name|
|Synonyms||Lofentanil; methyl (3S,4R)-1-(2-cyclohexylethyl)-4 -(cyclohexyl-propanoylamino)-3-methylpiperidine-4-carboxylate|
|(what is this?)|
Lofentanil is one of the most potent opioid analgesics known and is an analogue of fentanyl, which was developed in 1960. It is most similar to the highly potent opioid carfentanil (4-carbomethoxyfentanyl), only slightly more potent. Lofentanil can be described as 3-methylcarfentanil, or 3-methyl-4-carbomethoxyfentanyl. While 3-methylfentanyl is considerably more potent than fentanyl itself, lofentanil is only slightly stronger than carfentanil. This suggests that substitution at both the 3 and 4 positions of the piperidine ring introduces steric hindrance which prevents μ-opioid affinity from increasing much further. As with other 3-substituted fentanyl derivatives such as ohmefentanyl, the stereoisomerism of lofentanil is very important, with some stereoisomers being much more potent than others.
Lofentanil is very similar to carfentanil in effects, but has a longer duration of action. This makes it unsuitable for most practical applications, with carfentanil being the preferred agent for tranquilizing large animals, and short-acting derivatives such as sufentanil or remifentanil being preferred for medical use in human surgical procedures. The long duration and high lipophilicity of lofentanil has been suggested as an advantage for certain types of analgesia, but the main application for lofentanil at the present time is research into opioid receptors.
Side effects from lofentanil would be predicted to be similar to other potent fentanyl analogues, and would include sedation, euphoria, nausea, and pronounced itching and respiratory depression. Side effects from lofentanil might be particularly problematic given its reportedly long duration of action. Another side effect which is characteristic of fentanyl and its derivatives is their tendency to rapidly induce tolerance, due to their high binding affinity triggering rapid internalization of chronically activated opiate receptors. This might be expected to be a particular problem with lofentanil as it is not only one of the most potent drugs in the series, but also is longer acting than most other fentanyl analogues, meaning that development of tolerance triggered by receptor over-activation is likely to be especially rapid, occurring with as little as a single active dose.
- Gommeren W, Leysen JE. Binding properties of 3H-lofentanil at the opiate receptor. Archives Internationales de Pharmacodynamie et de Therapie. 1982 Jul;258(1):171-3.
- Meert TF, Lu HR, van Craenndonck H, Janssen PA. Comparison between epidural fentanyl, sufentanil, carfentanil, lofentanil and alfentanil in the rat: analgesia and other in vivo effects. European Journal of Anaesthesiology. 1988 Sep;5(5):313-21.
- Laduron PM, Janssen PF. Axoplasmic transport and possible recycling of opiate receptors labelled with 3H-lofentanil. Life Sciences. 1982 August 2;31(5):457-62.
- Foldes FF. Pain control with intrathecally and peridurally administered opioids and other drugs. Anaesthesiologie und Reanimation. 1991;16(5):287-98.
- Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. European Journal of Pharmacology. 1992 March 24;213(2):219-25.
- Huang XQ, Jiang HL, Luo XM, Chen KX, Zhu YC, Ji RY, Cao Y. Study on mechanism of interaction of nociceptin and opioids binding with opioid receptor-like 1 receptor. Acta Pharmacologica Sinica. 2000 Jun;21(6):536-46.
- Bot G, Blake AD, Li S, Reisine T. Fentanyl and its analogs desensitize the cloned mu opioid receptor. Journal of Pharmacology and Experimental Therapeutics. 1998 Jun;285(3):1207-18.